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ABSTRACT 
Background: The standard method used to determine the potency ofantihis- 
tamines is to assess the degree of suppression of skin response to histamine 
challenge. 
Objectives: The aims of this study were to compare the efficacy of 3 anti- 
histamines using a histamine challenge test and the usefulness of on-site evalu- 
ation with that of photographic evaluation of skin-test reactions. 
Methods: In this prospective, double-blind, crossover study, healthy volun- 
teers were given cetirizine 5 mg (CTZ-5) and 10 mg (CTZ-10), loratadine 10 mg 
(LOR), fexofenadine 60 mg BID (FEX), and placebo (PLC), in a randomly as- 
signed order, with an interval of at least 1 week between treatments. Before and 
0.5 to 24 hours after administration, the areas of flare and wheal induced by his- 
tamine iontophoresis were measured irectly (on site) by 1 evaluator and by 
another evaluator using photographic mages on a computer monitor. 
Results: Ten healthy volunteers (6 men, 4 women; mean age, 28.2 years 
[range, 20-39 years]; mean weight, 60.7 kg [range, 41-81 kg]) were enrolled. The 
data from 9 subjects were analyzed; the data from 1 subject were omitted 
because the subject used an over-the-counter cold medication containing 
diphenhydramine s veral times during the study. By both methods, all anti- 
histamines were shown to suppress flare significantly from 4 to 24 hours after 
administration. CTZ was most potent in suppressing both flare and wheal. For 
flare, the areas as measured using on-site evaluation were larger overall than 
those measured using photographic evaluation, but the shapes of the time- 
course graphs were similar for both. Overall, the flare area measurements 
started to decrease significantly from baseline values 4 hours after drug admin- 
istration, reached a nadir at 10.5 hours, and remained significantly lower com- 
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pared with baseline values at 24 hours. Comparisons between antihistamines 
showed significant differences in mean flare areas between the 2 doses of CTZ 
and LOR from 8 to 12 hours after administration i  both evaluation methods. 
The wheal areas were significantly reduced from baseline values by most of the 
antihistamines 4 to 12 hours after drug administration, reached their lowest 
values at 10.5 hours, and returned to near-baseline values at 24 hours. Com- 
parisons with PLC values at each time point, however, showed significant differ- 
ences only for CTZ-5 and CTZ-10 from 4 to 12 hours after administration. Com- 
parison between antihistamines showed significant differences in mean flare 
areas between the 2 doses of CTZ and LOR from 8 to 12 hours after adminis- 
tration in both evaluation methods. Although the flare areas measured by both 
methods correlated linearly (r = 0.90; P < 0.001), the correlation for wheal areas 
was weaker (r = 0.76; P < 0.001). 
Conclusions: In this study in healthy volunteers, single doses of CTZ 5 mg 
and CTZ 10 mg were more potent compared with single-dose LOR 10 mg and 
FEX 60 mg BID in suppressing skin response. Although linear correlations were 
found between skin-response areas, as measured by on-site and photographic 
evaluation, it was difficult to differentiate between wheal and flare by photo- 
graphic evaluation, especially when a typical wheal was suppressed to slightly 
edematous erythema by antihistamines. (Curt Ther Res Clin Exp. 2005;66:307- 
322) Copyright © 2005 Excerpta Medica, Inc. 
Key words: antihistamine, histamine iontophoresis, histamine challenge test, 
Image J, fexofenadine, loratadine, cetirizine, wheal, flare. 
INTRODUCTION 
Antihistamines are routinely used for the treatment of skin disorders accompa- 
nied by pruritus, most commonly urticaria. Most second-generation (nonse- 
dating) antihistamines are associated with less sedation and greater efficacy 
compared with first-generation antihistamines (eg, hydroxyzine, diphenhydra- 
mine). 1-3 However, the latter might be more potent and faster acting for 
dermographism compared with nonsedating antihistamines. 4 
The effect of antihistamines i  typically determined by assessing the degree 
of suppression of skin reaction induced by histamine challenge tests (eg, prick 
test, intracutaneous injection test). 2,3,5-s In many studies of antihistamines, the 
degree of skin reaction suppression has been assessed using direct measure- 
ments of the area of wheal and flare (on-site evaluation) over time after single- 
dose study drug administration. 2,3,5-'s 
The primary aim of the present study was to compare the suppressive 
effects of 3 widely used second-generation a tihistamines--cetirizine, lorata- 
dine, and fexofenadine--at s andard aily dosages (including number of doses 
per day and timing of administration [postprandial]). We also compared the 
usefulness of on-site evaluation with that of photographic evaluation of skin- 
test reactions. 
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SUBJECTS AND METHODS 
This prospective, double-blind, crossover study was conducted at the De- 
partment of Dermatology, School of Medicine, University of Tokushima, 
Tokushima, Japan. Healthy volunteers of both sexes and aged >18 years were 
eligible for the study. Patients who had any acute or chronic diseases; were 
receiving any medications; or who had a history of urticaria, including dermo- 
graphism, were ineligible. Pregnant or breast-feeding patients also were ex- 
cluded. Institutional review board approval was waived because, in the informal 
collective opinion of the university board members, the study was not thought 
to be dangerous, and all individuals were required to provide written informed 
consent o participate. All subjects were compensated for their involvement in 
the study. 
Study Drug Administration 
During the 3-month study period, subjects received, in a randomly assigned 
order, cetirizine hydrochloride 5 mg (CTZ-5), cetirizine hydrochloride 10 mg 
(CTZ-10), loratadine 10 mg (LOR), fexofenadine hydrochloride 120 mg (FEX), 
and pantetheine 200 mg (placebo [PLC]). Randomization of the order of admin- 
istration was performed using a computer-generated list of random numbers. 
Cetirizine and loratadine were given as a single dose in the morning (9:30 AM), 
with a matching placebo (pantetheine 100 mg) given in the evening (7:30 PM). 
Fexofenadine was divided into 2 doses of 60 rag, given once in the morning and 
once in the evening. Pantetheine was divided into 2 doses of 100 mg, given once 
in the morning and once in the evening. All study drugs were given by mouth 
with an unspecified amount of water 30 minutes after meals. An interval of at 
least 1 week separated the administration of each study drug. To ensure blind- 
ing, all study drugs were given an identical appearance by a third party, who 
wrapped each dose in a thin, soluble wafer. 
Two doses of CTZ were studied to compare dose responses. Pantetheine was 
used as the placebo because it was of similar size compared with the 3 active 
antihistamines and, according to the manufacturer (personal communication, 
Daiichi Pharmaceutical Company, Ltd., Tokyo, Japan), has not been associated 
with histamine-induced skin reactions. 
Exercise and alcohol consumption were prohibited uring the tests. The sub- 
jects were instructed not to use any medications, including over-the-counter 
drugs containing antihistamine or anti-inflammatory agent or any systemic or 
topical steroid, for at least 1 week before each test. 
Introduction of Histamine 
Before and 0.5, 1, 2, 4, 8, 10.5, 12, and 24 hours after the administration of the 
morning dose of each drug, histamine was applied to 1 of 9 sites (chosen by lot- 
tery) on the skin of the flexor forearm. Following the method described by 
Furue et al, 7 histamine 10 mg/mL, dissolved in distilled water, was dripped onto 
cotton packed into the applicator of an iontophoreser (UI-2060, BS Medical, 
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Tokyo, Japan) with a round skin-contact surface area of 19.6 mm 2, and a 0.1-mA 
electric current was applied for 1 minute. 
On-Site and Photographic Evaluations 
One dermatologist (H. Tsuda) (investigator A), blinded to the study drugs, 
was responsible for the on-site evaluations before (0 hour) and 0.5, 1, 2, 4, 8, 
10.5, 12, and 24 hours after dosing. For each on-site evaluation, the degree of the 
skin reaction was determined 15 minutes after the completion of iontophoresis, 
using direct measurement of flare and wheal, in which outlines of the central wheal 
and surrounding flare were traced with a fine-point marker onto a transparency 
sheet. The digital image of this transparent sheet and the 10<m scale was then 
obtained using an image scanner (CanoScan D2400U, Canon Inc., Tokyo, Japan). 
For each photographic evaluation, a color transparency of the entire area of 
the skin reaction, together with a scale, was obtained from a constant distance of 
35 cm using a single-lens reflex camera equipped with a ring-shaped flash bulb 
(OM-2 and T10 Rich Flash 1, Olympus Corporation, Tokyo, Japan). These slides 
were digitized in high resolution using a slide scanner (DS Elite II, Konica Minolta 
Holdings, Inc., Tokyo, Japan) and saved, in random order, to a computer. Another 
blinded ermatologist (H. Takiwaki) (investigator 13) was responsible for the quan- 
tification of the outlined area on the transparent sheet and the photographic eval- 
uations aRer all clinical trials were completed. The areas of flare (everything 
within the outer edge of the erythema) and wheal were measured using lmageJ 9
software for image analysis (National Institutes of Health, Washington, DC) by trac- 
ing the images with a computer mouse on a 17-inch monitor with 1280 x 1024-pixel 
resolution (FMV Deskpower CS/80LR, Fujitsu Ltd., Tokyo, Japan). 
Tolerability 
Adverse effects (AEs) were monitored using subject interview and physical 
examination by investigator A.
Statistical Analysis 
The results were analyzed using SAS version 8.2 (SAS Institute Inc., Cary, North 
Carolina). The data were analyzed using analysis of variance. The Dunnett test was 
used to compare the mean area of skin reaction of each drug with baseline and 
placebo values, and the Tukey test was used to compare the between-group differ- 
ences in the efficacy of the drugs. A P value <0.05 was considered statistically sig- 
nificant. The Pearson correlation coefficient was used to determine correlations 
between the data as measured by the 2 evaluators. 
The power analyses using the Dunnett test indicated that 10 subjects would be 
necessary to provide 80% power if the mean (SD) area of skin response was 
assumed to be 100 (20) mm 2 for the 4 treatment groups and 150 (20) mm 2 for the 
PLC group and the baseline values. Using the Tukey test, 8 subjects would be 
needed for 80% power if the mean (SD) area of skin response was assumed to be 
100 (15) mm 2 for the 4 treatment groups and 150 (15) mm 2 for the PLC group. 
310 
H. Tsnda and H. Takiwaki 
RESULTS 
Study Population 
Ten healthy volunteers (6 men, 4 women; mean age, 28.2 years [range, 20- 
39 years]; mean weight, 60.7 kg [range, 41-81 kg]) participated in the study. The 
data from 9 subjects were analyzed; the data from 1 subject were omitted be- 
cause the subject used an over-the-counter cold medication containing diphen- 
hydramine several times during the study. 
Suppression of Skin Reaction 
Representative skin reactions from 1 subject are shown in Figure 1. The 
changes in mean values of both flare and wheal areas from baseline to 24 hours 
after administration of each of the drugs are shown in the table and plotted in 
Figures 2 (flare) and 3 (wheal). 
Flare 
For flare, the areas as measured using on-site evaluation were larger overall 
than those measured using photographic evaluation, but the shapes of the 
time-course graphs were similar for both. Overall, the flare area measurements 
started to decrease significantly from baseline values 4 hours after drug admin- 
istration, reached a nadir at 10.5 hours, and remained significantly lower com- 
pared with baseline values at 24 hours. 
B 
J 
D 
Figure 1. Representative skin reactions from 1 subject (A) before and (B) 4 hours, 
(C) 8 hours, and (D) 24 hours after the administration of cetirizine 5 mg. 
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Time After Study Drug Administrat ion (h) 
Areas of histamine-induced flare before (time 0) and after the administra- 
t ion of an antihistamine or placebo (PLC) as measured using (A) on-site 
and (B) photographic evaluations (n = 9 in each treatment group). FEX = 
fexofenadine. *P < 0.01 versus baseline; tp < 0.001 versus PLC; Ip < 0.001 
versus baseline; §P < 0.05 versus Ioratadine (LOR); lip < 0.05 versus baseline; 
lp  < 0.01 versus LOR; #P < 0.05 versus PLC; **P < 0.01 versus PLC. 
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Figure 3. Areas of histamine-induced wheal before (time 0) and after the administra- 
tion of an antihistamine or placebo (PLC) as measured using (A) on-site and 
(B) photographic evaluations (n = 9 in each treatment group). *P < 0.01 ver- 
sus baseline; tp < 0.001 versus PLC; ~P < 0.001 versus baseline; §P< 0.05 ver- 
sus Ioratadine (LOR); lip < 0.05 versus baseline; 1p < 0.01 versus LOR; #P < 
0.05 versus PLC; **P < 0.01 versus PLC; ttp < 0.05 versus fexofenadine (FEX); 
~P < 0.01 versus FEX; §§P < 0.001 versus LOR; IIIIp < 0.001 versus FEX. 
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For CTZ-5, mean flare areas as measured using on-site evaluation were signif- 
icantly less compared with baseline at 4, 8, 10.5, 12, and 24 hours after admin- 
istration (P < 0.01, <0.001, <0.001, <0.001, and <0.05, respectively) and compared 
with PLC at the same time points (all, P < 0.001). These values as measured 
using photographic evaluation were significantly less compared with baseline 
at 4, 8, 10.5, and 12 hours after administration (all, P < 0.001), and compared 
with PLC at 4, 8, 10.5, 12, and 24 hours (P < 0.001, <0.001, <0.001, <0.001, and 
<0.05, respectively). 
For CTZ-10, mean flare areas as measured using on-site evaluation were signifi- 
cantly less compared with baseline at 4, 8, 10.5, 12, and 24 hours after administra- 
tion (P< 0.001, <0.001, <0.001, <0.001, and <0.01, respectively), and compared with 
PLC at the same time points (all, P < 0.001). These values as measured using pho- 
tographic evaluation were significantly less compared with baseline at 4, 8, 10.5, 
12, and 24 hours after administration (all, P < 0.001), and compared with PLC at the 
same time points (P < 0.001, <0.001, <0.001, <0.001, and <0.01, respectively). 
For LOR, mean flare areas as measured using on-site evaluation were signifi- 
cantly less compared with baseline at 8, 10.5, and 12 hours after administration 
(P < 0.001, <0.001, and <0.05, respectively), and compared with PLC at the same 
time points (P < 0.05, <0.05, and <0.01, respectively). These values as measured 
using photographic evaluation were statistically similar compared with base- 
line at all time points, and were significantly less compared with PLC at 12 hours 
after administration (P < 0.05). 
For FEX, mean flare areas as measured using on-site evaluation were signifi- 
cantly less compared with baseline at 4, 8, 10.5, 12, and 24 hours after administra- 
tion (P < 0.001, <0.001, <0.001, <0.01, and <0.05, respectively), and compared with 
PLC at the same time points (P < 0.001, <0.05, <0.001, <0.001, and <0.01, respec- 
tively). These values as measured using photographic evaluation were signifi- 
cantly less compared with baseline at 4, 8, 10.5, 12, and 24 hours after administra- 
tion (P < 0.001, <0.001, <0.001, <0.01, and <0.01, respectively), and compared with 
PLC at 4, 10.5, 12, and 24 hours (P < 0.05, <0.001, <0.01, and <0.05, respectively). 
For PLC, no significant differences versus baseline were found. 
Comparisons between antihistamines showed significant differences in mean 
flare areas between the 2 doses of CTZ and LOR from 8 to 12 hours after admin- 
istration in both evaluation methods (all, P ~ 0.05). 
When the AUC0_24 was regarded as being negatively correlated with the 
potency of overall suppression of the flare, the order of potency was CTZ-10 > 
CTZ-5 > FEX > LOR > PLC. 
Wheal 
The wheal areas were significantly reduced from baseline values by most of 
the antihistamines 4 to 12 hours after drug administration, reached their low- 
est values at 10.5 hours, and returned to near-baseline values at 24 hours. 
Comparisons with PLC values at each time point, however, showed significant 
differences only for CTZ-5 and CTZ-10 from 4 to 12 hours after administration. 
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For CTZ-5, mean wheal areas as measured using on-site evaluation were sig- 
nificantly less compared with baseline at 4, 8, 10.5, 12, and 24 hours after admin- 
istration (P < 0.001, <0.001, <0.001, <0.001, and <0.05, respectively), and com- 
pared with PLC at 4, 8, 10.5, and 12 hours (P < 0.05, <0.001, <0.001, and <0.001, 
respectively). These values as measured using photographic evaluation were 
significantly ess compared with baseline at 4, 8, 10.5, and 12 hours after admin- 
istration (all, P < 0.001), and compared with PLC at the same time points (P < 
0.05, <0.001, <0.001, and <0.001, respectively). 
For CTZ-10, mean wheal areas as measured using on-site evaluation were sig- 
nificantly less compared with baseline at 4, 8, 10.5, and 12 hours after adminis- 
tration (all, P < 0.001), and compared with PLC at the same time points (P < 0.01, 
<0.001, <0.001, and <0.001, respectively). These values as measured using pho- 
tographic evaluation were significantly ess compared with baseline at 4, 8, 10.5, 
and 12 hours after administration (all, P < 0.001), and compared with PLC at the 
same time points (P < 0.01, <0.001, <0.001, and <0.001, respectively). 
For LOR, mean wheal areas as measured using on-site evaluation were signif- 
icantly less compared with baseline at 4, 8, and 10.5 hours after administration 
(P < 0.01, <0.05, and <0.01, respectively). These values as measured using pho- 
tographic evaluation were significantly ess compared with baseline at 4, 8, and 
10.5 hours after administration (P < 0.01, <0.01, and <0.001, respectively). No 
statistically significant differences between LOR and PLC were found. 
For FEX, mean wheal areas as measured using on-site evaluation were signif- 
icantly less compared with baseline at 4, 10.5, and 12 hours after administration 
(all, P < 0.05). These values as measured using photographic evaluation were 
significantly less compared with baseline at 4 and 10.5 hours after administra- 
tion (P < 0.01 and <0.05, respectively). No statistically significant differences 
between FEX and PLC were found. 
For PLC, no significant differences versus baseline were found. 
Comparisons of the antihistamines showed significant differences between 
the 2 doses of CTZ and LOR and FEX at 10.5 and 12 hours after administration 
in both methods of evaluation (all, P ~ 0.05). 
Using AUC0_24, the strength of wheal suppression was CTZ-10 > CTZ-5 > FEX > 
LOR > PLC on on-site evaluation, but the order of LOR and FEX was reversed on 
photographic evaluation. 
Comparison of Results Obtained Using 
On-Site or Photographic Evaluation 
Figure 4A is a comparison of the area of flare as measured using on-site and 
photographic evaluation. Despite excellent linear correlation (r = 0.90; P < 
0.001), the slope of the regression line was 0.45, indicating that the flare area as 
measured using photographic evaluation was approximately half that measured 
using on-site evaluation. There was also good linear correlation in the case of 
the area of wheal (Figure 4B). The slope of the regression line was 0.75, indicat- 
ing that the absolute measurements obtained using the 2 methods were closer 
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for wheal than for flare. However, because many isolated points were plotted 
only on the x-axis or only on the y-axis, the correlation coefficient for the wheal 
was 0.76 (P < 0.001). These points represent reactions that were regarded as 
wheals by 1 evaluator but only as flares by the other. 
Tolerability 
No AEs were experienced by the subjects during the study. 
DISCUSSION 
Many studies have compared the suppressive effect of second-generation anti- 
histamines on histamine skin-test reactions. 1-s The results of the present study 
agreed, for the most part, with those of earlier studies. We were especially inter- 
ested in the suppressive ffect of CTZ-5 because 5 mg is half of the standard 
dose prescribed in Japan. Although the duration of the suppressive ffect of 
CTZ-5 was somewhat shorter than that of CTZ-10, the speed of its manifestation 
and its maximal strength were approximately the same as those of CTZ-10. 
Therefore, although the standard ose of CTZ in Japan is 10 mg QD, the option 
of 5 mg BID should be considered in future studies. 
However, the results of the present study were obtained with only 1 or 2 
administrations on a single day. The results of one study 3showed that even if 
the antihistamine effects of 2 drugs were different in the single-dose trial, the 
efficacy became similar when they were administered for 5 consecutive days. 
Because the results of the present study appear to be related to differences in 
the effect on the first day of treatment, it might not be reasonable to assume 
that the same findings can be used to predict he clinical effects in disorders 
that require continued rug use, such as chronic urticaria. 
Manifestation of the suppressive effects of the drugs examined in the present 
study was slower than in studies reported in the literature to date (MEDLINE 
search; key words: cetirizine and histamine-induced wheal; years: 2000-2005), most 
of which showed that suppression ofthe skin reactions was observed 1to 2 hours 
after antihistamine administration. 7,s,1°-16 Although the reason for these differences 
is unclear, they may have resulted from differences in the absorption rates of 
the drugs. In previous tudies, medications were administered with a large amount 
of water under fasting conditionsY ,6,s whereas the subjects in the present study 
received the medication after meals with an unspecified amount of water. The 
method by which histamine was introduced, and its concentration, might also 
explain why the suppressive ffect of antihistamines in other studies occurred 
sooner compared with that in the present study. 7,17 The concentration f histamine 
introduced in the skin might have been unexpectedly high for unknown reasons. 
Pantetheine was chosen as the placebo partly because the manufacturer 
indicated that the drug had no effect on skin-test reactions. However, this drug 
might have a weak suppressive effect on urticaria nd therefore might not have 
been an ideal placebo for use in this study. Is 
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We examined the differences between the results of on-site and photographic 
assessments of wheals and flares. Because the area of skin reaction changes 
each minute, and to avoid interinvestigator differences in area evaluations, it is 
typical in this type of clinical study that only 1 investigator measures the area 
of wheal and flare. 2 If photographic assessment was shown to be reliable, eval- 
uations could be performed by several examiners, which might increase objec- 
tivity and save time in this kind of clinical study. However, it is necessary to con- 
firm that the areas of skin reaction measured on-site and on photographic 
images show good linear correlation. Although our study showed good linear 
correlation between the corresponding flare areas, the absolute measurements 
obtained from the images were approximately half of those obtained with on- 
site assessment. In addition to the fact that defining the border for tracing 
depends on the subjective judgment of the evaluator, underestimation f the 
area might be inevitable with the photographic measurements because the res- 
olution of photographs i  inferior to on-site inspection and because the curved, 
3-dimensional surface of the forearm is projected onto the flat, 2-dimensional 
surface of the computer monitor. Another problem may be discrimination 
between wheal and flare. When histamine is introduced into the skin, a wheal 
with a clearly defined border develops that would be difficult to confuse with 
the surrounding erythema. However, when an antihistamine suppresses the 
reaction, erythema ccompanied by slight edema develops instead of the typi- 
cal wheal. Because a choice must be made between wheal and flare (ie, not 
wheal) in a clinical trial, assessments by the evaluators might differ, especially 
in the case of low-resolution photographic evaluation. This difference might 
then influence the assessment of the efficacy of drugs with similar potency. In 
our study, this was thought o be one reason for the reverse order of the sup- 
pressive ffects of LOR and FEX on wheals as assessed using the 2 methods. 
Further studies of the accuracy of photographic evaluation are needed to estab- 
lish this method as an appropriate alternative to on-site measurements. 
CONCLUSIONS 
In this study in healthy volunteers, ingle doses of CTZ 5 and 10 mg were more 
effective in suppressing histamine-induced skin response, as measured using 
on-site and photographic evaluation, compared with LOR and FEX. Although 
linear correlations were found between skin-test areas using the 2 methods of 
evaluation, it was difficult to differentiate between wheal and flare on photo- 
graphic evaluation, especially if a typical wheal was suppressed toslightly edem- 
atous erythema by antihistamines. 
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